Agenda Scientific Session – October 3, 2020

11:00 am ET (10 min) Welcome - Samm Masterson (introduce the planning committee) and Dr. Araya Puwanant (welcome everyone)

11:10 am ET (5 min) Introduction Dr. Kaminski (Deborah Gelinas, MD - Argenx)

11:15 am ET (30 min) Open with Dr. Henry Kaminski - Keynote Speaker
11:45 am ET (10 min) Q & A – Moderated by Araya Puwanant, MD

11:55 am ET (20 min) Poster Break

12:15 pm ET (5 min) Introduction MG Diagnostics (Christine Rowe, MBA - Alexion)

MG Diagnostics
12:20 pm ET (20 min) Presentations on Cell-Based Assays
  • Hans Frykman, MD, PhD
    LIVE CELL-BASED ASSAY FOR ANTIBODIES TO CLUSTERED ACETYLCHELINE RECEPTOR IN MYASTHENIA GRAVIS, CROSS VALIDATION, INTER-ASSAY STABILITY AND UTILITY IN A PAEDIATRIC COHORT SUSPECTED FOR MG
  • Jeffrey Guptill, MD
    VALIDATION OF A LIVE CLUSTERED CELL BASED ACETYLCHELINE RECEPTOR ASSAY IN A COHORT OF DOUBLE SERONEGATIVE DEFINITE MYASTHENIA GRAVIS PATIENTS

12:40 pm ET (5 min) Q & A - Moderated by Araya Puwanant, MD

12:45 pm ET (15 min)
  • Miriam Fichtner, MD
    AFFINITY MATURATION IS REQUIRED FOR PATHOGENIC MONOVALENT IGG4 AUTOANTIBODY DEVELOPMENT IN AUTOIMMUNE MYASTHENIA GRAVIS

1:00 pm ET (5 min) Q & A - Moderated by Araya Puwanant, MD
(5-minute transition)

1:10 pm ET (15 min) Data Blitz #1: Focused on Diagnostics
  • Ki Hoon Kim, MD
    ANTI-TITIN ANTIBODIES ARE FREQUENTLY OBSERVED IN PATIENTS WITH MYASTHENIA GRAVIS WHO EXPERIENCED THE RECURRENCE OF THYMOMA
  • Pritikanta Paul, MBBS
    REFLEX ALGORITHM FOR IMPROVING ACCURACY OF MYASTHENIA GRAVIS AUTOANTIBODY TESTING
Faraz S. Hussain, PhD  
PROTEOMIC PROFILING MAY REVEAL NOVEL BIOMARKERS FOR MYASTHENIA GRAVIS  
1:25 pm ET (5 min) Q & A - Moderated by Araya Puwanant, MD

1:30 pm ET (20 min) Exhibit Hall Break

1:50 pm ET (5 min) Introduction – MG, COVID and MG Registries (Omar Sinno, MD, MBA – UCB)

MG, COVID and MG Registries
1:55 pm ET (30 min) Presentations on COVID-related Topics
- Amanda Guidon, MD  
  FEASIBILITY AND ACCEPTABILITY OF REMOTE MONITORING OF PATIENTS WITH MYASTHENIA GRAVIS USING DIGITAL TECHNOLOGY
- Srikanth Muppidi, MD  
  COVID-19 ASSOCIATED RISKS AND EFFECTS IN MYASTHENIA GRAVIS (CARE-MG): AN INTERNATIONAL PHYSICIAN-REPORTED REGISTRY
2:25 pm ET (5 min) Q & A - Moderated by Shruti M. Raja, MD  
(5-minute transition)

2:35 pm ET (15 min) Data Blitz #2: Focused on COVID and Registries
- Kevin Li, MD  
  KNOWLEDGE AND PERCEPTIONS OF THE COVID-19 PANDEMIC AMONG PATIENTS WITH MYASTHENIA GRAVIS
- Megan Barra, PharmD, BCPS, BCCCP  
  IMPACT OF A MYASTHENIA GRAVIS DRUG-DISEASE INTERACTION CLINICAL DECISION SUPPORT TOOL ON PROVIDER PRESCRIBING
- Donald Sanders, MD  
  THE DUKE MYASTHENIA GRAVIS CLINIC REGISTRY: DESCRIPTION AND DEMOGRAPHICS
2:50 pm ET (5 min) Q & A - Moderated by Shruti M. Raja, MD

2:55 pm ET (20 min) Poster Break

3:15 pm ET (5 min) Introduction MG Clinical Trials (Tricia Gooljarsingh, PhD, CMPP - Momenta)

MG Clinical Trials
3:20 pm ET (30 min) Presentations on Clinical Trials
- Jeffrey Guptill, MD  
  A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PK, AND PD OF NIPOCALIMAB (M281) IN ADULTS WITH GENERALIZED MYASTHENIA GRAVIS
- James Howard, MD  
  TREATMENT OF PATIENTS WITH MYASTHENIA GRAVIS WITH EFGARTIGIMOD: RESULTS OF THE PHASE 3 ADAPT STUDY
3:50 pm ET (5 min) Q & A – Moderated by Srikanth Muppidi, MD  
(5-minute transition)
4:00 pm ET (15 min) Data Blitz #3: **Trials/New Strategies**

- Richard J. Nowak, MD, MS
  THE MYASTHENIA GRAVIS INEBILIZUMAB TRIAL (MINT): DESIGN OF RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDY OF AN ANTI-CD19 MONOCLONAL ANTIBODY IN GENERALIZED MYASTHENIA GRAVIS

- Suraj Muley, MD, FAAN
  TWO-YEAR POST-MARKETING SAFETY EXPERIENCE OF Eculizumab in Patients with Generalized Myasthenia Gravis in the United States

- Sangwook Oh, PhD
  Muscle-Specific Tyrosine Kinase Chimeric Autoantibody Receptor T Cells (MUSK-CAART) as a Precision Cellular Immunotherapy for Antigen-Specific B Cell Depletion in Musk Myasthenia Gravis (MG)

4:15 pm ET (5 min) Q & A - Moderated by Srikanth Muppidi, MD

4:15 pm ET (5 min) **Closing Remarks – Thank you(s) – Samm Masterson**

4:20 pm ET (30 min) **Poster Break and Exhibit Break**

**Agenda subject to change**